Search results for "cardiovascular events."

showing 10 items of 34 documents

Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project

2020

The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation …

0301 basic medicineMaleTime FactorsDiseaseUric acid.chemistry.chemical_compound0302 clinical medicineRisk FactorsUric Acid Cardiovascular events epidemiologyEpidemiologyMulticenter Studies as TopicHyperuricemiaStrokeCardiovascular events; Cardiovascular mortality; Uric acid; URRAHMiddle AgedPrognosisObservational Studies as TopicItalyCardiovascular DiseasesResearch DesignFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyCardiovascular mortalityUric acid · Cardiovascular mortality · Cardiovascular events · URRAHContext (language use)Cardiovascular eventHyperuricemiaRisk AssessmentCardiovascular events03 medical and health sciencesURRAHcardiovascular events; cardiovascular mortality; urrah; uric acidPharmacotherapyInternal medicineInternal MedicinemedicineHumansAgedRetrospective Studiesbusiness.industrymedicine.disease030104 developmental biologychemistryHeart failureUric acidbusinessUric acid030217 neurology & neurosurgeryCardiovascular events; Cardiovascular mortality; Uric acid; URRAH; Adult; Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Italy; Male; Middle Aged; Multicenter Studies as Topic; Observational Studies as Topic; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Uric AcidBiomarkers
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

2014

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

AdultComplementary TherapiesMalemedicine.medical_specialtyBenzylaminesAdolescentNauseaUrologyNaphthalenesDapoxetine Safety Cardiovascular events SyncopeSyncopeCardiovascular eventsYoung AdultInternal medicinePremature ejaculationmedicine80 and overCardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young AdultHumansProspective StudiesPremature EjaculationAdverse effectProspective cohort studyCardiovascular events; Safety; DapoxetineAgedCardiovascular events; Dapoxetine; Safety; Syncope; UrologyAged 80 and overSertralinebusiness.industrySettore MED/24 - UROLOGIAIncidence (epidemiology)Cardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young Adult; UrologyMiddle AgedDapoxetineCardiovascular events; Dapoxetine; syncope; SafetyDapoxetineAnesthesiaSerotonin Uptake InhibitorsObservational studymedicine.symptomSafetybusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugCardiovascular events Dapoxetine Safety Syncope
researchProduct

Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis

2011

We tested for the presence of coronary calcifications in patients with chronic renal disease not on dialysis and studied its progression in 181 consecutive non-dialyzed patients who were followed for a median of 745 days. Coronary calcifications (calcium score) were tallied in Agatston units by computed tomography, and the patients were stratified into two groups by their baseline calcium score (100 U or less and over 100 U). Survival was measured by baseline calcium score and its progression. Cardiac death and myocardial infarction occurred in 29 patients and were significantly more frequent in those patients with calcium scores over 100 U (hazard ratio of 4.11). With a calcium score of 10…

AdultMaleNephrologymedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentMyocardial Infarctioncardiovascular events chronic kidney disease coronary calcificationCoronary Artery DiseaseKaplan-Meier EstimateCohort StudiesCoronary artery diseasecardiovascular eventsRisk FactorsCalcinosisInternal medicinemedicineHumansMyocardial infarctionRenal Insufficiency ChronicDialysisAgedSettore MED/14 - Nefrologiabusiness.industryHazard ratiocoronary calcificationCalcinosisMiddle AgedPrognosismedicine.diseasecardiovascular eventSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryNephrologyDisease ProgressionCardiologyFemaleOriginal Articlebusinesschronic kidney diseaseKidney diseaseCalcification
researchProduct

Five-year prospective study on cardiovascular events, in patients with erectile dysfunction and hypotestosterone.

2017

Objective: Testosterone levels play a role in cardiac and vascular pathology. In the present study we investigated the prognostic significance of this hormone for cardiovascular outcome, in a 5-year follow-up. Materials and methods: Our cohort included 802 adult subjects, from 40 to 80 years. Patients were excluded if they had a past history of peripheral or coronary artery disease, and revascularization. A blood sample was drawn to valuate testosterone level, and we considered normal testosterone levels 300 ng/dl. FMD (flow mediated dilatation) of the brachial artery was assessed by measuring the increase of the brachial artery diameter during reactive hyperemia after transient forearm isc…

AdultMalemedicine.medical_specialtyBrachial ArteryUrologyCardiovascular event030204 cardiovascular system & hematologylcsh:RC870-923Settore MED/24 - UrologiaCardiovascular eventsCoronary artery diseaseCohort Studies03 medical and health sciences0302 clinical medicineErectile DysfunctionRisk Factorsmedicine.arteryInternal medicineSurveys and QuestionnairesmedicineHumansTestosteroneObesityProspective StudiesBrachial arteryProspective cohort studyStrokeReactive hyperemiaAgedDyslipidemiasAged 80 and overbusiness.industryPrevention030208 emergency & critical care medicineTestosterone (patch)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasePrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareErectile dysfunctionLogistic ModelsCardiovascular DiseasesCardiologybusinessDyslipidemiaFollow-Up StudiesArchivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
researchProduct

Lower plasma testosterone levels enhance the predictive value of endothelial dysfunction for future cardiovascular events: A 5-year prospective study.

2016

LETTER TO EDITOR

AdultMalemedicine.medical_specialtyTime FactorsUrology030204 cardiovascular system & hematologySettore MED/24 - UrologiaCardiovascular events.Cohort Studies03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicinemedicineHumansTestosterone030212 general & internal medicineEndothelial dysfunctionProspective StudiesEndothelial dysfunctionProspective cohort studyAgedAged 80 and overbusiness.industryMedicine (all)Testosterone (patch)Middle Agedmedicine.diseasePredictive valueSettore MED/11 - Malattie Dell'Apparato CardiovascolareDeathEndocrinologyCardiovascular DiseasesEndothelium VascularbusinessCardiology and Cardiovascular MedicineBiomarkersFollow-Up StudiesForecastingInternational journal of cardiology
researchProduct

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multi…

2017

Supplemental Digital Content is available in the text

Blood GlucoseMalerheumatoid arthritisCross-sectional studyType 2 diabetesTriglycerideArthritis Rheumatoid0302 clinical medicineRisk FactorsCardiovascular DiseasePrevalence030212 general & internal medicineMyocardial infarctionStrokeSubclinical infectionAged 80 and overMetabolic SyndromeMetabolic Syndrome XGeneral MedicineMiddle Agedinflammatory processCholesterolItalyCardiovascular DiseasesRheumatoid arthritisAtherosclerosiHypertensionComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleHumanResearch ArticleAdultmedicine.medical_specialtyAdolescentsubclinical atherosclerosisObservational Study03 medical and health sciencesYoung Adultcardiovascular eventsInternal medicinemedicineHumansTriglyceridesAged030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industryRisk Factor6900medicine.diseaseAtherosclerosisCross-Sectional StudiesDiabetes Mellitus Type 2Physical therapyMetabolic syndromebusinessRheumatismtraditional cardiovascular risk factorMedicine
researchProduct

Relationships between diuretic related hyperuricemia and cardiovascular events: data from the URRAH (URic acid Right for heArt Health) study.

2021

Objective Although the relationship between hyperuricemia and cardiovascular events has been extensively examined, data on the role of diuretic-related hyperuricemia are still scanty. The present study was designed to collect information on the relationship between diuretic-related hyperuricemia and cardiovascular events. Methods The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, observational cohort study involving data on individuals recruited from all the Italy territory under the patronage of the Italian Society of Hypertension with an average follow-up period of 122.3 ± 66.9 months. Patients were classified into four groups according to the diuretic use (y…

Cardiovascular eventMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologymedicine.medical_treatmentdiureticRenal functionHyperuricemiaCardiovascular eventcardiovascular events; cardiovascular mortality; diuretic; uric acid030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundcardiovascular events0302 clinical medicineuric acidRisk Factorscardiovascular mortalityInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineHyperuricemiaDiureticsHeart healthUric acid cardiovascular events diuretics epidemiologycardiovascular events cardiovascular mortality diuretic uric acidbusiness.industrySerum uric acidMiddle Agedmedicine.diseasechemistryHypertensionUric acidDiureticCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct